1. Introduction

Melasma and post-inflammatory hyperpigmentation (PIH) are among the most common presentations in aesthetic and general dermatology practice, and among the most frequently mishandled. Both are chronic, both are relapsing, and both are emotionally significant to the patient in a way that encourages the promise of removal rather than the offer of control.[15,16]

The commercial vocabulary of the field compounds the problem. The phrase “tyrosinase inhibitor” has become a generic marketing label attached to agents whose biochemical relationship with tyrosinase ranges from well-characterised direct interference to none at all. Because the category label carries clinical authority, it transfers unearned credibility from one agent to another.

This review therefore serves two aims. The first is to summarise the human clinical evidence for topical and systemic interventions intended to modulate pigment biology in melasma and PIH. The second is to propose a taxonomy that keeps mechanism, evidence and claim in alignment. It extends the cellular framework set out in the companion review of the fibroblast, melanocyte and keratinocyte by examining the melanocyte and its recipient keratinocyte as a functional pair rather than as separate chapters.

2. What counts as an inhibitor?

In this review, a direct enzyme-targeting agent is one with credible biochemical evidence of acting at tyrosinase or a closely connected melanogenic enzyme. That category includes hydroquinone, kojic acid, arbutin derivatives, azelaic acid, 4-n-butylresorcinol/rucinol and thiamidol. An indirect pigment modulator influences the pigment system without being principally defined by direct tyrosinase inhibition: TXA alters plasmin-associated and melanocyte–keratinocyte signalling; niacinamide reduces melanosome transfer; vitamin C is chiefly a redox-active and formulation-sensitive intervention; retinoids alter turnover, inflammatory tone and the handling of pigment within keratinocytes.[13,15]

This distinction corrects a common educational error in both directions. An agent can be a useful pigment therapy without being a direct tyrosinase inhibitor, and an agent with an elegant enzyme assay may lack the clinical evidence to justify a broad claim. Melanin synthesis begins with tyrosine conversion to L-DOPA and then dopaquinone under tyrosinase control, with downstream eumelanin and pheomelanin branches, melanosome maturation and transfer to keratinocytes. The relevant clinical unit is not the enzyme but the epidermal melanin unit — melanocytes, their dendrites, melanosomes and recipient keratinocytes — which behaves as a communications network rather than a one-enzyme assembly line.

3. Methods

Review question: in people with melasma or PIH, what are the efficacy and safety of topical or systemic interventions intended to inhibit melanogenesis, alter melanin transfer or otherwise directly modulate pigment biology?

Eligible evidence comprised human clinical studies — randomised controlled trials, controlled clinical studies and interpretable prospective single-arm studies. Cell, animal and ex-vivo studies were excluded from clinical-effect estimates and used only to explain mechanism. Energy-based procedures alone were excluded, although they could appear as a co-intervention where the active pigment-modulating intervention was identifiable. Outcomes of interest were MASI/mMASI, melanin index or colorimetry, global assessment, recurrence, quality of life and adverse events. Proprietary multi-active products with undisclosed composition were excluded.

The PubMed/MEDLINE query combined melasma or post-inflammatory hyperpigmentation with hydroquinone, TXA, kojic acid, arbutin, vitamin C/ascorbic acid, azelaic acid, niacinamide, cysteamine, rucinol/butylresorcinol, retinoids and thiamidol, with a clinical-trial, randomisation, placebo or control filter. It retrieved 409 records; rule-based title/abstract triage retained 320 for manual review; targeted primary-report verification across five prespecified streams generated ten study-level appraisals. This is presented as an interim selection framework, not as a final PRISMA flow diagram.

Randomised reports were appraised qualitatively using RoB-2-informed domains: randomisation and allocation, departures from intended intervention, missing outcome data, outcome measurement and selective reporting. Non-comparative evidence was assessed for baseline confounding, expectation effects, co-interventions and missing data. Numerical synthesis was not attempted, because studies differed in active, concentration, vehicle, application schedule, sunscreen instruction, delivery device, phototype, time point and outcome scale.

4. Results: hydroquinone and triple-combination therapy

Hydroquinone is the reference direct enzyme-targeting agent in this evidence base, and its activity is broader than a simplified “tyrosinase block”: the literature describes inhibition of melanin formation, effects on melanocyte nucleic-acid processes and melanosome effects.[15] The clinical question is not whether hydroquinone is active in isolation, but how it performs within a supervised, time-limited regimen with photoprotection and, where appropriate, adjunctive tretinoin and an anti-inflammatory steroid.

In an investigator-blinded multicentre randomised comparison, fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05% achieved a none-or-mild global severity score at eight weeks in 64.2% of participants, compared with 39.4% using hydroquinone alone (P<0.001).[1] Treatment-related adverse events were more frequent with triple combination, though none were severe. This supplies the strongest short-term comparative signal in the verified set, but it is an eight-week, formulation-specific and supervision-specific result. It does not license indefinite maintenance use, and it cannot separate the contribution of each ingredient.

Hydroquinone also demonstrates why safety language matters. Irritation can worsen pigmentary disease; prolonged, inappropriate or unsupervised use has been associated with adverse effects including exogenous ochronosis; and regulatory status differs internationally, from prescription medicine to restricted or prohibited cosmetic use. The defensible professional position is neither that hydroquinone is dangerous nor that it is a universal gold standard, but that it is a clinically active, regulation-sensitive medicine whose place depends on indication, supervision, duration and tolerance.

5. Results: kojic acid and alpha-arbutin

Kojic acid is a fungal-derived compound usually described as a copper-chelating tyrosinase-targeting agent, and it sits more comfortably in the direct enzyme-targeting category than vitamin C or TXA. Mechanism, however, is only the first step: instability, penetration, irritation and sensitisation limit it in practice, and controlled evidence is largely based on combination formulations rather than isolated comparisons.[14]

Alpha- and beta-arbutin are hydroquinone glycosides. They may interact with tyrosinase and reduce cellular melanogenesis, but apparent relative potency differs across assays, enzymes and substrates, and questions about hydroquinone formation under certain conditions reinforce the need to describe them as formulation-dependent direct TYR-interacting candidates rather than as “gentle hydroquinone.”

In an 80-participant comparative melasma study, a kojic-acid-plus-hydroquinone regimen produced the highest mean MASI improvement among several kojic-acid-containing combinations, but the study had small groups, an unblinded investigator, co-prescribed photoprotection and no hydroquinone-only arm.[3] A more recent evaluator-blinded split-face pilot compared alpha-arbutin 5% plus kojic acid 2% with hydroquinone–tretinoin–fluocinolone triple combination: at 12 weeks, melanin-index and mMASI differences between sides were not statistically significant, physician global assessment favoured triple combination, and erythema and stinging were more frequent with it.[4] The teaching value lies in both directions — a less irritating non-hydroquinone combination may be viable, yet a small multi-ingredient pilot cannot establish independent equivalence to hydroquinone.

6. Results: vitamin C as a redox-active adjunct

Vitamin C is routinely marketed as a tyrosinase inhibitor. A more accurate clinical description is a redox-active pigment modulator with formulation and delivery limitations. L-ascorbic acid can reduce oxidised melanogenic intermediates, scavenge reactive species and may interact with copper at the tyrosinase active site, but its clinical utility depends on stability, pH, vehicle, concentration, packaging and delivery.[13]

In a double-blind split-face study of 29 women, magnesium L-ascorbyl-2-phosphate delivered by iontophoresis improved a colorimetric pigmentation measure at 12 weeks compared with the control side.[5] This supports the delivery system tested rather than every home serum. An open-label 16-week study of 25% L-ascorbic acid with a penetration enhancer reported improvements in MASI, Mexameter and MelasQoL, but had no comparator and supplies very low-certainty evidence.[6]

Vitamin C therefore belongs in a morning antioxidant and photoprotection platform, where the aim is resilient skin function and prevention of repeated oxidative activation. It should not be presented as proof that an ordinary serum can replace disease-specific pigment therapy.

7. Results: tranexamic acid as indirect pigment modulation

TXA is not a direct tyrosinase inhibitor. It is a synthetic lysine analogue whose proposed pigment effects involve reversible interference with the plasminogen–plasmin system, reduced arachidonic-acid and prostaglandin signalling, and altered melanocyte–keratinocyte communication. The vascular and inflammatory dimensions of melasma make this indirect mechanism clinically attractive.[11,12]

In the verified melasma comparison by Janney and colleagues, topical TXA 5% and hydroquinone 3%, both with SPF 30, produced similar 12-week MASI reduction (27.0% versus 26.7%), with local erythema and irritation reported more frequently with hydroquinone.[7] The study was single-blind and its result is regimen-specific, but it illustrates a topical TXA signal with a potentially different local-tolerability profile. In acne-related PIH, TXA 5% solution and azelaic acid 20% both improved over 12 weeks with no significant between-group difference in PAHI, and fewer early local adverse effects with TXA; substantial attrition limits interpretation.[8]

For oral TXA, a meta-analysis of 28 randomised melasma trials found a statistically significant pooled signal at eight and 12 weeks, whereas topical and intradermal route analyses were not significant in that synthesis, with extremely high heterogeneity.[11] The responsible conclusion is not a dose recommendation. It is that oral TXA carries the more substantial aggregate melasma signal while requiring diagnosis-specific, safety-conscious and jurisdiction-aware assessment, and that topical, intradermal and oral routes must never be communicated as interchangeable.[17]

8. Results: niacinamide, azelaic acid, retinoids, rucinol and cysteamine

Niacinamide belongs primarily in the melanosome-transfer category. It is not a direct tyrosinase inhibitor, and its relevance to the melanocyte–keratinocyte unit is precisely that it addresses the recipient-cell side of pigmentation. Because it is commonly studied within multi-active products, isolated efficacy claims should remain modest.[14]

Azelaic acid is a useful bridge agent with tyrosinase-related and anti-inflammatory activity alongside established roles in acne and rosacea. In the acne-related PIH trial above it produced short-term PAHI improvement comparable to topical TXA.[8] The message is not that every pigmented condition should receive azelaic acid, but that a single agent may address both inflammatory disease and pigment where the diagnosis makes that biologically coherent.

4-n-butylresorcinol (rucinol) acts on tyrosinase and TRP-1. In a double-blind, vehicle-controlled split-face study of 20 women, 0.1% 4-n-butylresorcinol reduced melanin index more than vehicle at four and eight weeks;[9] a 0.3% rucinol serum study found a significant clinical-pigmentation advantage over vehicle at 12 weeks, supported by chromametry.[10] Both were small and short, providing low-certainty but mechanistically coherent evidence.

Retinoids are better framed as turnover-, transfer- and inflammation-modifying adjuncts than as primary direct enzyme inhibitors; their value in a night-time regimen is real, but irritation can itself create or worsen PIH. Cysteamine has a multi-pathway proposed mechanism that may include tyrosinase and peroxidase effects and glutathione-related activity, with placebo-controlled and hydroquinone-comparator trials described in recent reviews; variation in formulation, short-contact application and tolerability means it should not be compressed into a single class-wide effect size.[15]

9. Translating the evidence into a clinical teaching framework

The evidence supports a three-layer structure, presented as a clinical framework rather than a one-size-fits-all prescription. The first layer is foundational: morning antioxidant support where appropriate, broad-spectrum photoprotection with attention to visible light, and a barrier-supportive routine, with a night-time retinoid where tolerated. Its purpose is to reduce ongoing activation and to prevent active therapy from becoming an inflammatory trigger in its own right.

The second layer is diagnosis-led active pigment control. Melasma, acne-related PIH, dermatitis-related PIH and medication-associated pigmentation should not be assumed to share a target or a tolerance. A direct enzyme-targeting therapy may suit a melasma phenotype; an indirect modulator may be preferred where inflammatory, vascular or transfer-related biology dominates; and a combination is often more logical than a higher concentration of a single irritant active.

The third layer is treatment of the source of inflammation. Acne and rosacea are not pigment diseases, even though both may coexist with PIH. Disease-directed therapy belongs to the diagnosis-specific layer, and pigment control without control of acne, rosacea, dermatitis or procedural irritation treats the visible aftermath while perpetuating the cause.

The framework does not eliminate procedures; it disciplines them. Peels, microneedling and energy-based devices may have a role in selected patients, but every procedure can generate inflammation, and in an active, recurrent, barrier-impaired or PIH-prone phenotype, procedural escalation may amplify the problem. The appropriate endpoint in chronic melasma is reduction, stabilisation and maintenance — not a promise of permanent removal.

10. Language discipline

Because improvement in pigment is visible, emotionally important and slow, the field is unusually vulnerable to exaggerated claims. The remedy is not vagueness but precision: a mechanism described as a mechanism, a laboratory finding as a laboratory finding, a controlled clinical result as formulation-specific evidence, and a low-certainty signal as a signal.

In practice this means preferring “direct or tyrosinase-focused action” to “this blocks melanin”; “indirect pigment modulator” to “natural tyrosinase inhibitor”; “improvement, stabilisation and maintenance” to “permanent removal”; and route-specific statements for TXA rather than a single undifferentiated claim. The same discipline applies to procedures, where the clinician's ability to identify a high-risk phenotype, stage treatment, stop when irritation appears and provide follow-up matters more than the apparent strength of the device.

11. Limitations and research priorities

This review has substantive methodological limitations. It rests on one reproducible PubMed query and targeted primary verification rather than final multi-database retrieval. The 409 retrieved and 320 retained records have not undergone complete independent dual screening, and the verified evidence set is deliberately selective. A completed review should search at least MEDLINE, Embase or Scopus, CENTRAL and trial registries; deduplicate; apply two independent screeners; record full-text exclusions; present a final PRISMA 2020 flow diagram; and prespecify a formal certainty framework.

The clinical literature carries its own limitations. Many studies are short, underpowered and product-specific, and sunscreen instructions, vehicles, adherence, phototype, outcome measurement and co-administered procedures vary markedly. A fixed combination cannot establish the contribution of each ingredient. Future research should report consistent mMASI/MASI and colorimetric outcomes, include longer off-treatment follow-up for relapse, distinguish melasma from PIH, recruit diverse phototypes and publish intervention composition transparently.

12. Conclusion

Melasma and PIH should be taught through the melanocyte–keratinocyte unit, not through an undifferentiated list of skin lighteners. Hydroquinone, kojic acid and arbutin systems, azelaic acid, rucinol and thiamidol are best grouped as direct enzyme-targeting interventions. TXA, niacinamide, vitamin C, retinoids and cysteamine act through indirect, transfer, redox, inflammatory, signalling or turnover-related pathways. These categories overlap biologically but are not interchangeable clinically.

The evidence most strongly supports a structured combination approach in which photoprotection and barrier preservation are foundational, active pigment modulation is selected according to diagnosis and tolerance, and the inflammation that produces PIH is treated in parallel. The melanocyte and the keratinocyte are not separate chapters; they are a functional pair whose communication determines visible pigment.

13. Conflict of interest

The author is the founder and Medical Director of the Harley Street Institute, which provides commercial aesthetic training. This manuscript was handled independently of the journal's Editor-in-Chief.

14. Funding

None.